

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JAN 19 2001

TECH CENTER 1600/2900

Applicant(s): FEMAC, et al.

Serial No.: 09/428,082

Group Art Unit No.: 1642

Filed: October 22, 1999

Examiner: S. Huff

For: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Docket No.: A-527



RESPONSE TO OFFICE ACTION

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

In response to the Office Action dated December 12, 2000, Paper No. 6, Applicants elect Invention Group I, with traverse as described in the Remarks hereinafter.

Amendment

Please amend Claims 1, 9, 10, 11, and 22 as follows.

1. (Amended). A composition of matter of the formula



and multimers thereof, wherein:

F¹ is an Fc domain;

X¹ and X² are each independently selected from -(L¹)_c-P¹, -(L¹)_c-P¹-(L²)_d-P², -(L¹)_c-P¹-(L²)_d-P²-(L³)_e-P³, and -(L¹)_c-P¹-(L²)_d-P²-(L³)_e-P³-(L⁴)_f-P⁴

P¹, P², P³, and P⁴ are each independently [sequences of pharmacologically active peptides] IL-1 antagonist peptide sequences;L¹, L², L³, and L⁴ are each independently linkers; and

a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1.

9. (Amended). The composition of matter of Claim [8] 1 wherein the IL-1 antagonist peptide [sequence is] sequences are selected from SEQ ID NOS: 212, 907, 908, 909, 910, 917, and 979.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

January 11, 2001
Date

Christina A. Jenkins
Signature